Cancer Biomarkers Could Help Guide Treatment
April 19, 2007
(HealthDay News)—New biomarkers could help doctors predict how individual cancer patients will respond to drug or radiation therapy, new research suggests.
The findings were detailed in a number of studies presented this month at the annual meeting of the American Association for Cancer Research in Los Angeles.
Being able to determine how a patient will respond to specific cancer therapies should boost cancer treatment, experts say.
In one study, researchers at Lawrence Berkeley National Laboratory identified gene expression signatures that could serve as biomarkers to predict how a woman will respond to the breast cancer drugs lapatinib and CI-1040.
"Individuals respond differently to different therapeutics because there are substantial differences in the spectrum of genetic, biological and epigenetic (non-inherited) characteristics between breast cancers," explains Joe W. Gray, director of the Life Sciences Division at Lawrence Berkeley National Laboratory. "We need better ways to identify how we can best tailor existing therapies to individuals and how to target experimental agents," he adds.
In another study, French researchers said they found that mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in colorectal cancer patients. For people with this mutation, the drug is likely to be ineffective and could even harm them.
"Because of variety of different effective agents may now be available for any given type of cancer, deciding which treatment regimen is likely to be the most effective and the least toxic is more complicated than ever," says Dr. Pierre Laurent-Puig, a professor of oncology at the University of Paris Descartes. "Characterizing the factors that are predictive of toxicity and efficacy could lead to significant improvement in both the quality of treatment and outcomes," he says.
A third study by Vanderbilt University researchers identified 44 peptides (protein fragments) that can be used to determine response to tyrosine kinase inhibitor drug therapy--combined with radiation therapy--in patients battling lung or brain cancer.
"It is difficult to assess the response of cancer in the brain or lung to treatment, since those neoplasms [tumors] are difficult to access safely," says Dr. Roberto Diaz, a radiation-oncology resident at the Vanderbilt-Ingram Cancer Center. "With the proper biomarkers, physicians may be able to tell if a patient is not responding to therapy and alter their treatment strategy accordingly. This study provides us with a starting point for understanding how tumors physiologically respond to therapy and a noninvasive technique for monitoring that response," he notes.
In yet another study, scientists at the Translational Genomics Research Institute found that 164 genes are involved in regulating the vulnerability of squamous cell head and neck cancer cells to the drug lapatinib.
For more information about tumor markers, visit the U.S. National Cancer Institute Web site.
<< Back
April 19, 2007
(HealthDay News)—New biomarkers could help doctors predict how individual cancer patients will respond to drug or radiation therapy, new research suggests.The findings were detailed in a number of studies presented this month at the annual meeting of the American Association for Cancer Research in Los Angeles.
Being able to determine how a patient will respond to specific cancer therapies should boost cancer treatment, experts say.
In one study, researchers at Lawrence Berkeley National Laboratory identified gene expression signatures that could serve as biomarkers to predict how a woman will respond to the breast cancer drugs lapatinib and CI-1040.
"Individuals respond differently to different therapeutics because there are substantial differences in the spectrum of genetic, biological and epigenetic (non-inherited) characteristics between breast cancers," explains Joe W. Gray, director of the Life Sciences Division at Lawrence Berkeley National Laboratory. "We need better ways to identify how we can best tailor existing therapies to individuals and how to target experimental agents," he adds.
In another study, French researchers said they found that mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in colorectal cancer patients. For people with this mutation, the drug is likely to be ineffective and could even harm them.
"Because of variety of different effective agents may now be available for any given type of cancer, deciding which treatment regimen is likely to be the most effective and the least toxic is more complicated than ever," says Dr. Pierre Laurent-Puig, a professor of oncology at the University of Paris Descartes. "Characterizing the factors that are predictive of toxicity and efficacy could lead to significant improvement in both the quality of treatment and outcomes," he says.
A third study by Vanderbilt University researchers identified 44 peptides (protein fragments) that can be used to determine response to tyrosine kinase inhibitor drug therapy--combined with radiation therapy--in patients battling lung or brain cancer.
"It is difficult to assess the response of cancer in the brain or lung to treatment, since those neoplasms [tumors] are difficult to access safely," says Dr. Roberto Diaz, a radiation-oncology resident at the Vanderbilt-Ingram Cancer Center. "With the proper biomarkers, physicians may be able to tell if a patient is not responding to therapy and alter their treatment strategy accordingly. This study provides us with a starting point for understanding how tumors physiologically respond to therapy and a noninvasive technique for monitoring that response," he notes.
In yet another study, scientists at the Translational Genomics Research Institute found that 164 genes are involved in regulating the vulnerability of squamous cell head and neck cancer cells to the drug lapatinib.
For more information about tumor markers, visit the U.S. National Cancer Institute Web site.
<< Back
